Literature DB >> 19364649

Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones.

Xue Zhi Zhao1, Kasthuraiah Maddali, B Christie Vu, Christophe Marchand, Stephen H Hughes, Yves Pommier, Terrence R Burke.   

Abstract

Using 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one and 4,5-dihydroxy-1H-isoindole-1,3(2H)-dione based HIV-1 integrase inhibitors as display platforms, we undertook a thorough examination of the effects of modifying the halogen substituents on a key benzyl ring that is hypothesized to bind in a hydrophobic pocket of the integrase.DNA complex. Data from this study suggest that in general dihalo-substituted analogues have higher potency than monohalo-substituted compounds, but that further addition of halogens is not beneficial.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364649      PMCID: PMC2747502          DOI: 10.1016/j.bmcl.2009.03.122

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  15 in total

1.  Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors.

Authors:  Haolun Jin; Ruby Z Cai; Laura Schacherer; Salman Jabri; Manuel Tsiang; Maria Fardis; Xiaowu Chen; James M Chen; Choung U Kim
Journal:  Bioorg Med Chem Lett       Date:  2006-05-24       Impact factor: 2.823

2.  Benzyl amide-ketoacid inhibitors of HIV-integrase.

Authors:  Michael A Walker; Timothy Johnson; B Narasimhulu Naidu; Jacques Banville; Roger Remillard; Serge Plamondon; Alain Martel; Chen Li; Albert Torri; Himadri Samanta; Zeyu Lin; Ira Dicker; Mark Krystal; Nicholas A Meanwell
Journal:  Bioorg Med Chem Lett       Date:  2007-06-14       Impact factor: 2.823

3.  Docking studies on a new human immunodeficiency virus integrase-Mg-DNA complex: phenyl ring exploration and synthesis of 1H-benzylindole derivatives through fluorine substitutions.

Authors:  Stefania Ferro; Laura De Luca; Maria Letizia Barreca; Nunzio Iraci; Sara De Grazia; Frauke Christ; Myriam Witvrouw; Zeger Debyser; Alba Chimirri
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

4.  Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.

Authors:  Wim G Verschueren; Inge Dierynck; Katie I E Amssoms; Lili Hu; Paul M J G Boonants; Geert M E Pille; Frits F D Daeyaert; Kurt Hertogs; Dominique L N G Surleraux; Piet B T P Wigerinck
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

5.  Novel HIV-1 integrase inhibitors derived from quinolone antibiotics.

Authors:  Motohide Sato; Takahisa Motomura; Hisateru Aramaki; Takashi Matsuda; Masaki Yamashita; Yoshiharu Ito; Hiroshi Kawakami; Yuji Matsuzaki; Wataru Watanabe; Kazunobu Yamataka; Satoru Ikeda; Eiichi Kodama; Masao Matsuoka; Hisashi Shinkai
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

6.  Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors.

Authors:  X Chen; M Tsiang; F Yu; M Hung; G S Jones; A Zeynalzadegan; X Qi; H Jin; C U Kim; S Swaminathan; J M Chen
Journal:  J Mol Biol       Date:  2008-05-01       Impact factor: 5.469

7.  Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.

Authors:  Jessica Marinello; Christophe Marchand; Bryan T Mott; Anjali Bain; Craig J Thomas; Yves Pommier
Journal:  Biochemistry       Date:  2008-08-15       Impact factor: 3.162

8.  2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors.

Authors:  Xue Zhi Zhao; Elena A Semenova; B Christie Vu; Kasthuraiah Maddali; Christophe Marchand; Stephen H Hughes; Yves Pommier; Terrence R Burke
Journal:  J Med Chem       Date:  2007-12-21       Impact factor: 7.446

Review 9.  Raltegravir: an integrase inhibitor for HIV-1.

Authors:  Teresa H Evering; Martin Markowitz
Journal:  Expert Opin Investig Drugs       Date:  2008-03       Impact factor: 6.206

10.  From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety.

Authors:  Alessia Petrocchi; Uwe Koch; Victor G Matassa; Barbara Pacini; Kara A Stillmock; Vincenzo Summa
Journal:  Bioorg Med Chem Lett       Date:  2006-10-25       Impact factor: 2.823

View more
  13 in total

1.  Development of tricyclic hydroxy-1H-pyrrolopyridine-trione containing HIV-1 integrase inhibitors.

Authors:  Xue Zhi Zhao; Kasthuraiah Maddali; Mathieu Metifiot; Steven J Smith; B Christie Vu; Christophe Marchand; Stephen H Hughes; Yves Pommier; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2011-03-21       Impact factor: 2.823

2.  MK-0536 inhibits HIV-1 integrases resistant to raltegravir.

Authors:  Mathieu Métifiot; Barry Johnson; Steven Smith; Xue Zhi Zhao; Christophe Marchand; Terrence Burke; Stephen Hughes; Yves Pommier
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  6,7-Dihydroxy-1-oxoisoindoline-4-sulfonamide-containing HIV-1 integrase inhibitors.

Authors:  Xue Zhi Zhao; Kasthuraiah Maddali; Steven J Smith; Mathieu Métifiot; Barry C Johnson; Christophe Marchand; Stephen H Hughes; Yves Pommier; Terrence R Burke
Journal:  Bioorg Med Chem Lett       Date:  2012-10-27       Impact factor: 2.823

4.  Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity.

Authors:  Barry C Johnson; Mathieu Métifiot; Yves Pommier; Stephen H Hughes
Journal:  Antimicrob Agents Chemother       Date:  2011-10-28       Impact factor: 5.191

5.  Selectivity for strand-transfer over 3'-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site.

Authors:  Mathieu Métifiot; Barry C Johnson; Evgeny Kiselev; Laura Marler; Xue Zhi Zhao; Terrence R Burke; Christophe Marchand; Stephen H Hughes; Yves Pommier
Journal:  Nucleic Acids Res       Date:  2016-07-01       Impact factor: 16.971

Review 6.  6,7-Dihydroxyisoindolin-1-one and 7,8-Dihydroxy-3,4-Dihydroisoquinolin- 1(2H)-one Based HIV-1 Integrase Inhibitors.

Authors:  Xue Zhi Zhao; Mathieu Metifiot; Steven J Smith; Kasthuraiah Maddali; Christophe Marchand; Stephen H Hughes; Yves Pommier; Terrence R Burke
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

Review 7.  HIV-1 IN inhibitors: 2010 update and perspectives.

Authors:  Christophe Marchand; Kasthuraiah Maddali; Mathieu Métifiot; Yves Pommier
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  Diketoacid-genre HIV-1 integrase inhibitors containing enantiomeric arylamide functionality.

Authors:  Xue Zhi Zhao; Kasthuraiah Maddali; Christophe Marchand; Yves Pommier; Terrence R Burke
Journal:  Bioorg Med Chem       Date:  2009-05-08       Impact factor: 3.641

9.  Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants.

Authors:  Xue Zhi Zhao; Steven J Smith; Mathieu Métifiot; Barry C Johnson; Christophe Marchand; Yves Pommier; Stephen H Hughes; Terrence R Burke
Journal:  J Med Chem       Date:  2014-02-10       Impact factor: 7.446

10.  Activities, crystal structures, and molecular dynamics of dihydro-1H-isoindole derivatives, inhibitors of HIV-1 integrase.

Authors:  Mathieu Métifiot; Kasthuraiah Maddali; Barry C Johnson; Stephen Hare; Steven J Smith; Xue Zhi Zhao; Christophe Marchand; Terrence R Burke; Stephen H Hughes; Peter Cherepanov; Yves Pommier
Journal:  ACS Chem Biol       Date:  2012-12-24       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.